Thomas Teisseyre Sells 24,188 Shares of Hyperfine (NASDAQ:HYPR) Stock

Hyperfine, Inc. (NASDAQ:HYPRGet Free Report) COO Thomas Teisseyre sold 24,188 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $1.21, for a total transaction of $29,267.48. Following the sale, the chief operating officer directly owned 354,648 shares of the company’s stock, valued at approximately $429,124.08. This represents a 6.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Hyperfine Price Performance

Shares of NASDAQ:HYPR traded up $0.02 during midday trading on Wednesday, hitting $1.17. The company had a trading volume of 352,549 shares, compared to its average volume of 502,890. Hyperfine, Inc. has a twelve month low of $0.53 and a twelve month high of $2.22. The stock has a market cap of $113.69 million, a price-to-earnings ratio of -2.66 and a beta of 1.09. The business’s 50-day simple moving average is $1.16 and its 200-day simple moving average is $1.20.

Hyperfine (NASDAQ:HYPRGet Free Report) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. Hyperfine had a negative return on equity of 95.09% and a negative net margin of 262.29%.The company had revenue of $5.29 million for the quarter, compared to analyst estimates of $5.30 million. As a group, sell-side analysts forecast that Hyperfine, Inc. will post -0.57 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on HYPR shares. Zacks Research upgraded shares of Hyperfine to a “hold” rating in a research report on Thursday, March 19th. Lake Street Capital boosted their target price on shares of Hyperfine from $2.00 to $2.50 and gave the company a “buy” rating in a report on Thursday, March 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperfine in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $1.45.

View Our Latest Report on Hyperfine

Hedge Funds Weigh In On Hyperfine

Several large investors have recently modified their holdings of HYPR. EP Wealth Advisors LLC purchased a new position in shares of Hyperfine during the 4th quarter worth $34,000. Sanctuary Advisors LLC raised its holdings in Hyperfine by 130.9% in the 4th quarter. Sanctuary Advisors LLC now owns 39,938 shares of the company’s stock valued at $39,000 after buying an additional 22,638 shares during the period. Kathmere Capital Management LLC purchased a new stake in Hyperfine in the 4th quarter valued at about $51,000. Millennium Management LLC acquired a new position in Hyperfine in the fourth quarter valued at about $55,000. Finally, Cerity Partners LLC acquired a new position in Hyperfine in the fourth quarter valued at about $59,000. Institutional investors and hedge funds own 15.03% of the company’s stock.

About Hyperfine

(Get Free Report)

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.

Recommended Stories

Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.